Home
About Us
Leadership Team
Board of Directors
Investors
Our Science
Our Science
Presentations & Publications
Our Portfolio
Our Platform
Our Pipeline
Our Lead Program – AMV564
Careers
Current Openings
News
Contact us
Home
About Us
Leadership Team
Board of Directors
Investors
Our Science
Our Science
Presentations & Publications
Our Portfolio
Our Platform
Our Pipeline
Our Lead Program – AMV564
Careers
Current Openings
News
Contact us
Latest News
2021
04 June, 2021
Press Releases
Press Releases 2021
Amphivena Presents New Monotherapy and First Combination Therapy Clinical Data in Solid Tumor Patients
12 April, 2021
Press Releases
Press Releases 2021
Amphivena Presents Translational Data Highlighting the Cytokine Profile for its Lead Clinical Candidate, AMV564 at the AACR 2021 Virtual Annual Meeting
2020
16 December, 2020
Press Releases
Press Releases 2020
Amphivena Therapeutics Announces First Patient Dosed in the Phase 1 Dose Expansion of AMV564
06 December, 2020
Press Releases
Press Releases 2020
Novel AML patient selection assay for AMV564, Amphivena’s lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting
09 November, 2020
Press Releases
Press Releases 2020
Amphivena Presents Clinical Update and Translational Data of AMV564 in Solid Tumor Patients at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
23 June, 2020
Press Releases
Press Releases 2020
Amphivena Presents Translational Data for its Lead Clinical Candidate, AMV564 at the AACR 2020 Virtual Annual Meeting II
17 June, 2020
Press Releases
Press Releases 2020
Amphivena Announces Upcoming Oral Presentation at AACR Virtual Annual Meeting II
29 May, 2020
Press Releases
Press Releases 2020
Amphivena Presents Data from First-in-Human Study of AMV564 in Solid Tumor Patients at the ASCO Virtual Annual Meeting 2020
28 May, 2020
Press Releases
Press Releases 2020
Amphivena Therapeutics to Present at the Jefferies Virtual Healthcare Conference
14 May, 2020
Press Releases
Press Releases 2020
Clinical Data for Amphivena Therapeutics’ Lead Program to be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
2019
09 December, 2019
Press Releases
Press Releases 2019
Amphivena Reports Data on Phase 1 Study of AMV564 at ASH Annual Meeting
02 December, 2019
Press Releases
Press Releases 2019
Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer
07 November, 2019
Press Releases
Press Releases 2019
Rationale for Expansion of AMV564 into Solid Tumors
16 October, 2019
Press Releases
Press Releases 2019
Amphivena Initiates Solid Tumor Clinical Trial
01 July, 2019
Press Releases
Press Releases 2019
Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting
05 March, 2019
Press Releases
Press Releases 2019
Amphivena Expands Executive Team – Victoria Smith, Ph.D. Named Chief Scientific Officer; Peter Van Vlasselaer, Ph.D. Appointed Executive Chairman of the Board
2018
03 December, 2018
Press Releases
Press Releases 2018
Amphivena Presents at ASH First-in -Human Phase 1 Clinical Data on AMV564
2017
09 December, 2017
Press Releases
Press Releases 2017
Amphivena Presents Preclinical Data at ASH that Points to a Potentially New Treatment for MDS Patients
29 November, 2017
Press Releases
Press Releases 2017
Amphivena Receives Orphan Drug Designation for AMV564, a Novel CD33/CD3 T-Cell Engagement Therapy for the Treatment of Acute Myeloid Leukemia
11 September, 2017
Press Releases
Press Releases 2017
Amphivena Announces New Key Leadership and Advisors – Tekla Invests in Series B Round
2016
10 August, 2016
Press Releases
Press Releases 2016
Amphivena Therapeutics Announces Acceptance of Investigational New Drug (IND) Application for AMV564 and Planned Phase 1 Trial Initiation
2015
26 May, 2015
Press Releases
Press Releases 2015
Amphivena Therapeutics to Present Data on Novel Cancer Immunotherapy at 2015 ASCO Annual Meeting
07 April, 2015
Press Releases
Press Releases 2015
Amphivena Therapeutics Achieves Development Milestones Under Agreement With Janssen